Dr. Jessica Haberer presented the talk, “Does the monitoring of medication packaging tell us what we need to know about TB treatment adherence” on October 11, 2017 at the UNION meeting in Guadalajara, Mexico. It was one of four presentations highlighting the use of technology to support TB medication adherence. In the talk, Dr. Haberer summarizes the need for adherence-informed approaches to TB treatment, particularly as programs move away from directly observed therapy and toward self-administered therapy. She reviews several types of electronic adherence monitors (e.g., evriMED, Wisepill) and 99DOTS (a cell phone-based reporting system), all of which can be linked to data-driven, patient-centered intervention within a public health delivery context. Dr. Haberer discusses the evidence for impact from these approaches, as well as accuracy and acceptability to patients. She also comments on use of these approaches at scale and identifies areas for future research and development.
Donors such as Bill & Melinda Gates Foundation, USAID and Global Affairs Canada are supporting the TB REACH Wave 6 initiative to fund innovation and research to (i) improve detection, linkage to treatment and reporting of TB, and (ii) improve TB treatment adherence and outcomes. The Arcady Group founder, Bruce Thomas, helped launch the Wave 6 call, presenting an overview of the TB adherence technologies and highlighting areas of interest and focus for Wave 6 applicants.
The presentation concluded with the following recommendations for country programs interested in gaining experience with, and insights about, the acceptability and impact of adherence technologies:
- Proposals utilizing and evaluating adherence technologies and technology-enhanced patient management are invited/encouraged.
- Although 99DOTS, V-DOT, and evriMED are of particular interest, proposals involving other technologies/approaches also are invited.
- It is desirable to have work done in, and have strong involvement from, high burden country programs.
To find out more: https://lnkd.in/dAb24R7.
The Arcady Group founder, Bruce Thomas, led the Stop TB Partnership’s Focus Group Workshop On Digital Adherence Technologies. At this meeting, innovators such as Everwell Health (99DOTS), Wisepill Technologies (evriMED medication monitor), Keheala (SMS-based behavioral counseling) and SureAdhere Mobile Technology (V-DOT) were connected with representatives of key NGO implementers and country programs (including Zimbabwe, Philippines, Moldova, and South Africa) to discuss opportunities for experimentation and uptake of digital adherence technologies through TB REACH Wave 6 grants. Bruce and Ram Subbaraman shared new evidence and insights about the importance of treatment adherence to avoid TB relapse. Download our presentation slides here.